Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 2, 2010, Pages 279-283

  Otsuka, Isao ^a   Takahashi, Shinji ^a   O'uchi, Kumi ^a   Akimoto, Natsuko ^a   Hanari, Kyoko ^a   Ogaki, Yoko ^a   Enatsu, Yi Hsien ^a   Takigawa, Aya ^a   Takaya, Hisamitsu ^a   Tanaka, Ayuko ^a   Kaseki, Hanako ^a   Yamada, Takuhiro ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CLINICAL FEATURE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA;

EID: 79960759142     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. http://ganjoho.jp/public/statistics/pub/nenji.html
2. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282, 2006.
3. Rose PG: Endometrial carcinoma. N Engl J Med 335:640-649, 1996.
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467, 1998.
5. O'Regan R, Cisneros A, England GM, et al: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth. J Natl Cancer Inst 90:1552-1558, 1998. (Pubitemid 28535720)
6. Saadat M, Truong T, Kader HA, et al: Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer. Comparison of cohorts treated with and without tamoxifen. Cancer 110:31-37, 2007. (Pubitemid 46986415)
7. Jordan VC and Assikis VJ: Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer Res 1:467-472, 1995.
8. Slomovitz BM, Sun CC, Ramirez PT, et al: Does tamoxifen use affect prognosis in breast cancer patient who develop endometrial cancer ? Obstet Gynecol 104:255-260, 2004.
9. International Breast Cancer Study Group: Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749-1759, 2004.
10. Marttunen MB, Cacciatore B, Hietanen P, et al: Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 84:897-902, 2001. (Pubitemid 32385831)
11. Shibutani S, Ravindernath A, Terashima I, et al: Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 61:3925-3931, 2001. (Pubitemid 32720952)
12. Fisher BM, Costantino JP, Remond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project B-14. J Natl Cancer Inst 86:527-537, 1994. (Pubitemid 24111008)
13. Barakat RR, Wong G, Curtin JP, et al: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55:164-168, 1994. (Pubitemid 24366620)
14. Magriples U, Naftolin F, Schwartz PE, et al: High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490, 1993. (Pubitemid 23071046)
15. Mignotte H, Lasset C, Bonadona V, et al: Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 76:325-330, 1998. (Pubitemid 28282929)
16. Bergman L, Beelen MLR, Gallee MPW, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356:881-887, 2000.
17. Swerdlow AJ, Jones ME for the British Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97:375-384, 2005. (Pubitemid 40425956)
18. Levine DA, Argenta PA, Yee CJ, et al: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222-4227, 2003. (Pubitemid 46606192)
19. Guillem JG, Wood WC, Moley JF, et al: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642-4660, 2006.
20. Kauff ND and Barakat RR: Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 25:2921-2927, 2007. (Pubitemid 47123156)
21. Lavie O, Hornreich G, Arie AB, et al: BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 96:28-32, 2000. (Pubitemid 30336275)
22. Risinger JI, Parrett JC, Watson P, et al: Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77:1836-1843, 1996.
23. Love CDB, Muir BB, Scrimgeour JB, et al: Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17:2050-2054, 1999. (Pubitemid 29318834)
24. Barakat RB: Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol 17:1967-1968, 1999.